Formulation Development And Evaluation Of Atazanavir Nanoparticles

Abstract

Atazanavir is one of the effective antiviral drugs used in the treatment of HIV. It is a lipophilic drug encountering various problems such as poor solubility, rapid first-pass metabolism and pH based dissolution. To overcome these issues, atazanavir nanoparticles (AZNP1 to AZNP5) were formulated. The formulations prepared were evaluated for drug content, entrapment efficiency, particle size, surface morphology and drug release. AZNP3 nanoparticles of particle size (227.9nm), surface charge (-20.7mV) was found to be optimum. The percentage of drug release was 99.85 up to 24h. The results of evaluation studies support the potential and futuristic applications of atazanavir nanoparticles in the treatment of HIV. In conclusion, the nanoparticles can be a promising drug delivery of atazanavir at a controlled rate.